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± 0.2 / -1.4 ± 0.4 SD, r = -0.24, p<0.01), Z-score (0.7 ± 0.5 / -0.2 ± 0.1 / -0.3 ± 0.2 / -0.9 ±
0.3 SD, r = -0.22, p<0.01). Osteopenia (T-score < -1.0) was found in 20% and 29% pts in
NYHA I-II and III-IV, respectively, and osteoporosis (T-score < -2.5) in 9% pts in NYHA III-
IV. There were no osteopenia or osteoporosis in controls. CHF pts with osteopenia or
osteoporosis compared to pts with normal BMC had reduced peak VO2 (13.9±0.9 vs
16.5±0.8 mL/kg/min), decreased fat and lean mass (17±1 vs 23±1 kg, 52±1 vs 57±1 kg,
respectively), increased C-reactive protein level (48±37 vs 13±5 mg/L), increased par-
athormone level (113±18 vs 73±10 pg/mL), reduced levels of dehydroepiandrosterone
sulphate, total, free and bioavailable testosterone (54±10 vs 97±15 µg/dL, 3.0±0.6 vs
4.5±0.3 ng/mL, 9±2 vs 16±2 ng/dL, 212±49 vs 367±36 ng/dL, respectively) (all p<0.05).
During the 18-month follow-up, 18 (15 %) pts died. Reduced bone mass (BMC-total < vs
> 3 kg) was related to poor survival in univariate analysis (RR=3.7, 95%CI - 1.2-11.3,
p<0.05), not when adjusted for NYHA class, peak VO2.
Conclusions. Bone loss accompanied by reduced fat and lean mass is observed in CHF
pts, in particular in advanced stages, and is related to poor outcome. Hyperparathyroid-
ism, adrenal and gonadal andropenia, inflammation may be important in the pathogene-
sis of bone loss in CHF, but further studies are needed.
1108-118 Comparative Yield of Clinical, Laboratory, 
Echocardiographic, and Neurohormonal Predictors of 
Outcome in Heart Failure Patients (Val-HeFT Data)
Lidia Staszewsky, Maylene Wong, Simona Barlera, Elisa Carretta, Serge Masson, 
Roberto Latini, Aldo P. Maggioni, Jay N. Cohn, Gianni Tognoni, Istituto di Ricerche 
Farmacologiche, Milan, Italy, VA Greater Los Angeles Healthcare System, Los Angeles, 
CA
Introduction: Numerous variables are prognostic of HF, but not all are widely available.
Val-HeFT data which contain a full complement of bedside, laboratory, echocardio-
graphic, and neurohormonal endpoints were analyzed for comparative predictive value.
Methods: Pooled baseline data from the history (H), physical examination (PE), and labo-
ratory from Val-HeFT included age, sex, etiology, NYHA class, symptoms, signs, labora-
tory, EF and LVIDd. Except for age, continuous variables were considered above and
below the median. Adjusted RR for mortality at study endpoint and 95% CI from a multi-
variate Cox analysis with stepwise selection are presented. Results: Patients with all data
available (N=4284) were predominantly white, aged 63 y, males/ females=4/1, 98%
NYHA class II & III, 57% ischemic etiology, EF=26.8±7.2% (mean±SD),
LVIDd=6.9±0.9cm. 828 patients died over 23 months follow-up. BNP, LVIDd, NE and cre-
atinine were the strongest independent predictors of mortality. The other significant pre-
dictors were variables from the H & PE. Leg, thigh or sacral edema showed a high RR
but a low prevalence; high grade of dyspnea on effort increased the RR > 30% (table).
NYHA class and EF were not statistically significant. Conclusions: Independent markers
of mortality were findings from the H & PE, review of systems, laboratory, and M-mode
echocardiography. Therefore, conventional bedside evaluation with a limited set of labo-
ratory data can provide a powerful aggregate for predicting mortality.
1108-119 Clinical Outcome in Patients With Preoperative 
Congestive Heart Failure Undergoing Coronary Artery 
Bypass Graft Surgery
Mohan Babapulle, Kristian B. Filion, Seema Haider, Louise Pilote, Mark J. Eisenberg, 
Jewish General Hospital, Montreal, PQ, Canada
Background: Coronary artery bypass graft surgery (CABG) is frequently performed in
patients with chronic congestive heart failure (CHF). However, there have been no large-
scale studies specifically examining clinical outcome in patients with pre-operative CHF
undergoing CABG.
Methods: We extracted data from the resource and cost accounting systems of 5 U.S
and 4 Canadian hospitals on 12,017 consecutive patients undergoing CABG between
1997-2001. Of these patients 1,176 (9.8%) had pre-operative CHF, and 10,841 (90.2%)
did not. We examined the post-operative length of stay (LOS) and in-hospital mortality in
patients with and without CHF. We performed a log transformation of LOS data, and iden-
tified independent predictors of LOS using a multiple linear regression model. We
adjusted for covariates of mortality using multivariate logistic regression.
Results: Patients with pre-operative CHF were older (69.9 ± 9.8 years vs. 64.9 ± 10.2
years), and were more likely to be female (65.0% vs. 77.2%), to have diabetes (36.9% vs.
24.9%) and to have cerebrovascular disease (10.2% vs. 5.1%). The CHF group was also
more likely to undergo non-elective CABG (69.9% vs. 55.2%) and reoperation (8.9% vs.
5.6%). Compared to patients without CHF, patients with CHF had a longer unadjusted
post-operative LOS (11.0 ± 0.5 days vs. 6.8 ± 0.07 days). After adjusting for clinical differ-
ences, the LOS in CHF patients was 38% longer than those without CHF (95% Confi-
dence Interval (CI) 33-43%, P<0.0001). Patients with CHF also had a higher unadjusted
in-hospital mortality rate compared to patients without CHF (6.0% vs. 1.3%). The
adjusted odds ratio for mortality was 3.52 (95% CI 2.36-5.25, P<0.0001).
Conclusions: Compared to patients without pre-operative CHF, patients with pre-opera-
tive CHF have a longer post-operative LOS, and a more than 3-fold higher in-hospital
mortality rate following CABG.
1108-120 A Gap in Care: Heart Failure Patients Undergoing Major 
Noncardiac Surgery
Adrian F. Hernandez, David J. Whellan, Sharon Stroud, Jie Lena Sun, Christopher M. 
O'Connor, James G. Jollis, Duke Clinical Research Institute, Durham, NC
Background:Perioperative care has reduced the complications in patients with coronary
artery disease (CAD) undergoing major noncardiac surgery but outcomes of heart failure
(HF) patients are unknown.
Methods: Using the 1997-98 Standard Analytic File 5% Sample of Medicare beneficia-
ries, we identified pts with an index HF admission. From this cohort, we identified pts with
a subsequent major noncardiac surgery within one year of the index HF hospitalization.
We used a multivariable logistic regression model to provide adjusted mortality and read-
mission rates in pts after noncardiac surgery. Patients hospitalized with CAD and later
had a major noncardiac surgery as well as the remaining pts (Control) who had similar
surgery served as reference groups.
Results: There were 23,340 HF pts and 28,710 CAD pts who were hospitalized and sur-
vived to discharge. In the next year, there were 1,532 HF pts (6.56%) and 1,757 (6.12%)
CAD pts who underwent surgery. There were 44,512 pts in the Control group. After
accounting for demographics and comorbid conditions, the risk adjusted inpatient and
30-day mortality in discharged pts was HF-15.8%, CAD- 8.0% and Control-7.3%
(p<0.001). The risk-adjusted 30-day readmission rate was HF- 21.0%, CAD-14.3% and
Control-11.0% (p<0.001).
Conclusion: HF patients undergoing major noncardiac surgery suffer significant morbidity
and mortality despite advances in perioperative care while patients with CAD have simi-
lar mortality compared to a more general population.
1108-121 Survival Benefit With Spironolactone Therapy Is Not 
Related to Reduced hsCRP Levels in Severe Congestive 
Heart Failure: Results From a RALES Substudy
Michel F. Rousseau, Annie R. Robert, Ronald Van Beneden, Virginie de Coninck, Sylvie 
A. Ahn, Jean-Marie Ketelslegers, Hubert G. Pouleur, University of Louvain, Brussels, 
Belgium
In the RALES study, Spironolactone (Spiro), an aldosterone receptor antagonist,
decreased mortality and morbidity in patients with severe congestive heart failure. To
clarify the mechanism of action, particularly the role of inflammation on progression of
heart failure and cardiovascular events, the effects of Spiro (25 mg/daily) on plasma con-
centrations of high sensitivity C-reactive protein (hsCRP) were assessed in a subset of
113 patients (NYHA III-IV, mean EF : 25%) at entry (T0) into study, at 3 months (T3) and
at 6 months (T6) and compared the changes to the Placebo group. 54 patients were
included in the Spiro group and 59 in the Placebo group. Results were expressed in mg/
dL, geometric mean [95% CI] and data were compared using a Student t-test on a
logtransformed scale. The hsCRP changes from baseline are expressed by the ratios T3/
T0 and T6/T0 (see table).
At baseline, hsCRP levels were elevated with no significant differences between groups.
During follow-up, similar hsCRP reductions from baseline were observed in Placebo and
Spiro groups reaching statistical significance at T6 (-40%, p=0.02 and -41%, p=0.02,
respectively), with values close to normal. None of the between groups comparisons
reached statistical significance.
Thus, in this small cohort of patients with severe congestive heart failure, there was no
Covariate Frequency(%) RR [95%CI] Chi-
Square 
p_value
BNP>97 pg/mL 50 1.85 [ 1.56 - 2.15] 61 <.0001
LVIDd>6.8 cm 54 1.49 [1.23 - 1.72] 28 <.0001
Norepinephrine>394 pg/
mL
50 1.39 [1.21 - 1.61] 20 <.0001
Creatinine>107 µmol/L 51 1.40 [1.21 - 1.61] 20 <.0001
Edema leg/thigh/sacrum 2 2.01 [1.45 - 2.77] 18 <.0001
Digoxin prescribed 67 1.40 [1.19 - 1.65] 16 <.0001
Age>70y 29 1.33 [1.14 - 1.54] 14 0.0002
Ischemic Etiology 57 1.32 [1.14 - 1.54] 14 0.0002
Dyspnea on effort 3+/4+ 33 1.30 [1.12 - 1.50] 12 0.0004
BB not prescribed 65 1.31 [1.12 - 1.54] 12 0.0006
Paroxysmal nocturnal 
dyspnea
9 1.40 [1.14 - 1.72] 10 0.0014
Systolic BP<121 mmHg 49 1.23 [1.07 - 1.42] 9 0.0032
BMI >22 kg/m2 10 1.32 [1.08 - 1.60] 8 0.0055
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evidence that Spiro had greater effects on hsCRP than placebo, suggesting that reduced
inflammation was not a major mechanism underlying the clinical benefit of Spiro in this
setting.
1108-122 Cost-Effectiveness of Eplerenone in Patients With Heart 
Failure Postmyocardial Infarction
William S. Weintraub, Zefeng Zhang, Elizabeth Mahoney, Richard Willke, John Spertus, 
Bertram Pitt, Emory University, Atlanta, GA
Background: Aldosterone blockade with eplerenone prolonged life in the setting of heart
failure (HF) post myocardial infarction (MI) in the EPHESUS trial. 6,632 patients in 37
countries with HF post-MI were randomized to eplerenone 25-50 mg/day vs placebo,
mean follow-up 16 with 478 deaths in the eplerenone group, 554 with placebo group (rel-
ative risk 0.85, 95% CI 0.75 to 0.96). We consider the cost-effectiveness of eplerenone
based on EPHESUS.
Methods: Trial wide efficacy and resource utilization were used. Unit costs in multiple
countries were applied to hospitalizations and ER visits by DRG and outpatient proce-
dures. Medication use was costed using average wholesale price. Initial hospitalization
costs were not included in the base case as study drug was initiated towards the end of
this hospitalization. Eplerenone is not yet marketed; drug cost will be available in late
2003 or early 2004. Life expectancy was estimated from Framingham data, discounted
3%. A similar analysis based on the Worcester Heart Attack Registry will be presented as
well. Results: 
Cost-effectiveness based on Ephesus trial results with Framingham and Worcester sur-
vival models will be presented for the United States and the Netherlands.
Conclusions: Independently of drug costs, aldosterone blockade with eplerenone in the
setting of heart failure post-MI is a dominant strategy, preventing events, prolonging life,
and lowering resource use without increasing cost. Cost-effectiveness with drug cost in-
cluded will be presented.
1108-123 The Effect of Eplerenone on Markers of Cardiac 
Fibrosis: Insights From EPHESUS
Faiez Zannad, Jean-Marie Ketelslegers, Ernesto L. Schiffrin, Gordon Williams, Susan 
Garthwaite, Weizhong He, Rajiv Patni, Bertram Pitt, Clinical Investigation Center 
INSERM-CHU de Nancy Hôpital Jeanne d'Arc, Dommartin-les Toul Cedex, France
Background: Chronic heart failure patients with elevated markers of cardiac fibrosis
have an increased risk of death; aldosterone blockade reduces this risk (Circ
2000;102:2700-2706). EPHESUS showed that selective aldosterone blockade with
eplerenone reduced total mortality by 15% (P=0.008) and CV mortality/hospitalization by
13% (P=0.002) vs placebo when added to standard care in post-MI patients with systolic
left ventricular dysfunction (SLVD) (NEJM 2003;348:1309-21). This substudy evaluated
the correlation between procollagen type III amino-terminal peptide (PIIINP) and out-
comes in patients treated with eplerenone vs placebo.
Methods: There were 476 patients in the substudy. Baseline blood samples were drawn
with patients in a seated position, the morning of randomization (mean = 7, range 3-14
days, after index MI). Subsequent levels were drawn at Week 4, and Months 3, 6, and 9.
Results: Baseline PIIINP levels were elevated among nonsurvivors in both arms (non-
survivors 4.14 µg/L vs survivors 3.98 µg/L), and were associated with an increased risk
of negative outcomes. At baseline, PIIINP levels were 4.0 µg/L in eplerenone and pla-
cebo groups. Eplerenone significantly reduced PIIINP levels over time. Changes were
statistically different from placebo beginning at Week 4 (eplerenone 4.1 µg/L [+4%] vs
placebo 4.5 µg/L [+15%]; P<0.001). By Month 9, eplerenone reduced PIIINP levels from
baseline -11.5% vs -2.3% for placebo patients (P=0.002).
Conclusions: Eplerenone decreased PIIINP levels, a marker of cardiac collagen deposi-
tion associated with an increased risk of total mortality and CV mortality/hospitalization.
These findings suggest an association between the action of eplerenone on aldosterone,
myocardial fibrosis, and improved outcomes, and support the prognostic value of PIIINP
levels in patients with post-MI SLVD.
1108-124 Effect of Exercise Training on Sleep Disordered 
Breathing in Severe Heart Failure Patients
Dov Freimark, Peretz Lavie, Meirav Ingbir, Ehud Schwammenthal, Michael Motro, 
Yehuda Adler, Heart Failure Clinic, Sheba Medical Center, Tel hashomer, Israel, Cardiac 
Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel
Background: Chene-Stokes respiration (CSR) is common in patients with congestive
heart failure (CHF) and is associated with nocturnal oxygen desaturation, sleep disrup-
tion, impaired exercise tolerance and prognosis. Exercise training (ET) has been shown
to be effective in restoring functional capacity and improving quality of life in these
patients. The aim of our study was to determine the impact of ET on CSR in severe CHF
patients.
Methods: Forty-four severe stable CHF patients (mean LVEF 21±7%) participated in an
18 week ET program. Thirty of them underwent an initial sleep study prior to the ET, and
of these 25 underwent an additional sleep study at the end of the ET. A modified Bruce
exercise test was performed by all patients at the beginning and end of the ET period.
Based on the initial sleep recordings patients were divided into two groups with (N=18,
respiratory disturbance index (RDI) of >20 events/hr, Group A) and without (N=12, RDI of
<19 events/hr, Group B) significant CSR. A follow-up post ET sleep study was completed
by 15 patients from Group A and 10 from Group B.
Results: There was no significant difference between Groups A and B in pre-training
exercise test duration (mins), 5.9±3.9 versus 4.6±3.0, p=0.34, respectively. Exercise
duration improved significantly post ET in both Groups, 10.6±2.3 mins, p<0.01 (Group A)
and 8.7±2.7 mins, p<0.01 (Group B). A significant reduction in CSR was noted in Group
A, RDI 38.3±18.1 before ET, compared to 22.6±15.9 after training, p=0.005. However, the
number of episodes did not change in Group B, RDI 12.0±3.1 before and 16.3±7.8 after
training, p=0.19.
Conclusion: Severely ill CHF patients with severe CSR can benefit from ET.
1108-125 Can the Response to Exercise Training Be Predicted in 
Patients With Heart Failure?
Neil Smart, Leanne Short, Brian Haluska, Thomas H. Marwick, University of 
Queensland, Brisbane, Australia
Background. Exercise training in heart failure (CHF) has favorable effects on quality of
life, LV function and functional capacity, but some pts do not respond and supervision
makes this approach resource-intensive. We sought to identify pts most likely to benefit,
thus permitting optimal use of resources.
Methods. A 16 week program of aerobic training (cycle ergometer 3 times/week, at 70%
Peak VO2) was undertaken by 32 pts (30 male, age 63±11 y) with baseline EF <35%
(mean 27±8%) and peak VO2 12±4 ml/kg/min. The etiology of CHF was ischemic heart
disease in 20 pts (63%). At baseline, 8- and 16 -weeks, pts underwent 2D echo, meta-
bolic exercise testing and quality of life evaluation with Minnesota Living with Heart Fail-
ure (MLWHF) and Hare-Davis Cardiac Depression (HD) questionnaires.
Results. Both MLWHF and HD scores improved at 8 and 16 wks (p=0.001). Resting EF
improved by 13% at 8 wks (p=0.009) and 17% at 16 weeks (p=0.05). Peak VO2
increased at 8 wks (to 13±4, p=0.04) and at 16 wks (15±4, p<0.001). Change of VO2 at
16 weeks was predicted by baseline and 8 wk peak VO2 (model r2 = 0.77, see figure).
Conclusions. QOL, EF and peak VO2 were improved by training, although QOL and EF
changes plateau in the first 8 weeks while further changes in peak VO2 occur between 8
and 16 wks. Change in peak VO2 at 16 wks may be predicted from baseline and 8 wk
peak VO2 data, suggesting a means of selecting pts for this resource intensive therapy. 
hsCRP Placebo p value hsCRP Spiro p value Placebo vs Spiro
T0 0.67 [0.46-0.97] 0.61 [0.45-0.82] 0.54
T3 0.50 [0.34-0.73] 0.39 [0.28-0.53] 0.25
T6 0.37 [0.25-0.54] 0.31 [0.22-0.43] 0.30
T3/T0 0.78 [0.54-1.12] 0.18 0.67 [0.44-1.01] 0.053 0.75
T6/T0 0.60 [0.39-0.92] 0.02 0.59 [0.39-0.91] 0.02 0.80
Placebo Eplerenone Difference 95% CI
Initial Hospital Costs $6,164 $6,140 -$24 -$46,-$1
Re-Hospitalization Costs $8,271 $8,073 -$198 -$959, $482
Medication Costs(exclusive of 
eplerenone)
$3,314 $3,382 $67 -$51, $192
Outpatient Tests $534 $568 $34 -$34, $104
ER Visits $47 $43 -$4 -$10, $2
Total Follow-up Costs $12,167 $12,065 -$101 -$859, $669
F/u Heart Failure 
Hospitalizations
0.1862 0.1437 -0.0425 -0.0694, -0.0162
Total f/u Hospitalizations 0.9007 0.8481 -0.0526 -0.1250, 0.0187
Life Years (in trial) 1.30 1.33 0.0304 0.0026, 0.0567
Lost Life Expectancy in Years 
(Framingham)
0.6404 0.5390 0.1014 0.0306, 0.1740
